Literature DB >> 36068715

Denosumab, an effective osteoporosis treatment option for men.

Sung Hye Kong1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36068715      PMCID： PMC9449201          DOI： 10.3904/kjim.2022.261

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN： 1226-3303            Impact factor:   3.165


× No keyword cloud information.
  10 in total

1.  A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

Authors:  Eric Orwoll; Christence S Teglbjærg; Bente L Langdahl; Roland Chapurlat; Edward Czerwinski; David L Kendler; Jean-Yves Reginster; Alan Kivitz; E Michael Lewiecki; Paul D Miller; Michael A Bolognese; Michael R McClung; Henry G Bone; Östen Ljunggren; Bo Abrahamsen; Ugis Gruntmanis; Yu-Ching Yang; Rachel B Wagman; Suresh Siddhanti; Andreas Grauer; Jesse W Hall; Steven Boonen
Journal:  J Clin Endocrinol Metab       Date:  2012-06-21       Impact factor: 5.958

2.  Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study.

Authors:  Sakae Tanaka; Hideki Mizutani; Eri Tsuruya; Ryoko Fukuda; Kiyoka Kuge; Naoki Okubo
Journal:  J Bone Miner Metab       Date:  2021-01-02       Impact factor: 2.626

Review 3.  New and developing pharmacotherapy for osteoporosis in men.

Authors:  Luigi Gennari; John P Bilezikian
Journal:  Expert Opin Pharmacother       Date:  2018-01-19       Impact factor: 3.889

4.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

Authors:  David L Kendler; Christian Roux; Claude Laurent Benhamou; Jacques P Brown; Michael Lillestol; Suresh Siddhanti; Hoi-Shen Man; Javier San Martin; Henry G Bone
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

5.  Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 years.

Authors:  Delphine Farlay; Sébastien Rizzo; David W Dempster; Shuang Huang; Arkadi Chines; Jacques P Brown; Georges Boivin
Journal:  J Bone Miner Res       Date:  2022-03-24       Impact factor: 6.741

6.  Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea.

Authors:  Yumie Rhee; Dong-Gune Chang; Jeonghoon Ha; Sooa Kim; Yusun Lee; Euna Jo; Jung-Min Koh
Journal:  Endocrinol Metab (Seoul)       Date:  2022-06-03

7.  Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.

Authors:  Naoki Okubo; Shigeyuki Matsui; Toshio Matsumoto; Toshitsugu Sugimoto; Takayuki Hosoi; Taisuke Osakabe; Ko Watanabe; Hideo Takami; Masataka Shiraki; Toshitaka Nakamura
Journal:  Calcif Tissue Int       Date:  2020-08-25       Impact factor: 4.333

8.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

Review 9.  Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.

Authors:  N C W Harvey; E V McCloskey; P J Mitchell; B Dawson-Hughes; D D Pierroz; J-Y Reginster; R Rizzoli; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2017-02-07       Impact factor: 4.507

10.  Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.

Authors:  P D Miller; N Pannacciulli; J P Brown; E Czerwinski; B S Nedergaard; M A Bolognese; J Malouf; H G Bone; J-Y Reginster; A Singer; C Wang; R B Wagman; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2016-06-06       Impact factor: 5.958
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.